Table 2.
Study and intervention characteristics of primary studies included in reviews
| Number of Reviews (l) | M (SD) | |
|---|---|---|
| Delivery modes reported | 11 | |
| In-person, individual | 10 | |
| In-person, group | 8 | |
| App-based | 0 | |
| Mhealth | 1 | |
| Online, including email | 7 | |
| Telephone | 11 | |
| Text messages | 5 | |
| Study and Intervention duration reported | 7 | |
| Intervention length min. (weeks) | 1.55 (1.68) | |
| Intervention length max. (weeks) | 64.90 (27.05) | |
| Study length min. (weeks) | 4.03 (2.26) | |
| Study length max. (weeks) | 71.34 (22.72) | |
| Control/Comparison type reporteda | 8 | |
| Inactive/asssessment only (% of primary studies) | 0.81 (0.16) | |
| Information-only (% of primary studies) | 0.07 (0.10) | |
| Active (% of primary studies) | 0.11 (0.14) | |
| Intervention components reported | 9 | |
| Reminder systems | 8 | |
| Case management/referral | 1 | |
| Adherence incentives | 5 | |
| Additional support systems reported | 9 | |
| Directly observed therapy | 1 | |
| Home visits | 4 | |
| Individual medication managers | 0 | |
| Social support | 8 | |
| Treatment assistants | 0 | |
| Adherence measures reporteda | 11 | |
| Electronic (% of primary studies) | 0.30 (0.32) | |
| Pharmacy (% of primary studies) | 0.19 (0.07) | |
| Pill count (% of primary studies) | 0.19 (0.12) | |
| Self-report (% of primary studies) | 0.48 (0.20) | |
| “Other” type (% of primary studies) | 0.06 (0.03) | |
Note. Inactive/assessment-only control groups included standard/usual care.
l = number of reviews. M = mean. SD = Standard deviation
a
At the review level, % of primary studies that reported these variables.